REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Anti-Anxiety Stack

Cognitive Enhancementbeginner

81

synergy

81
Peptides

2

Avg Daily mcg

700

Level

beginner

Added

May 17, 2026

Overview

The Anti-Anxiety Stack pairs the anxiolytic peptide Selank with Delta Sleep-Inducing Peptide (DSIP) to address both daytime anxiety and the sleep disruption that typically accompanies chronic stress. Selank''s anxiolytic mechanism operates primarily through allosteric modulation of GABA-A receptors — similar to benzodiazepines but without binding to the benzodiazepine site itself. This produces anxiolysis without sedation, cognitive impairment, tolerance development, or physical dependence. Additionally, Selank stabilizes enkephalin levels in the blood (endogenous opioid peptides that modulate mood and pain), preventing the rapid enzymatic degradation that occurs under chronic stress conditions. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. It modulates sleep architecture by promoting delta-wave (slow-wave) sleep — the deepest restorative phase that is typically disrupted by anxiety and chronic stress. DSIP also normalizes cortisol rhythms (reducing elevated evening cortisol that prevents sleep onset) and modulates GABA and serotonin systems. Clinical studies in humans have demonstrated improved sleep quality and reduced time to sleep onset without the hangover effects of pharmacological sleep aids. The combination addresses the anxiety-insomnia cycle from both ends: Selank during the day reduces the stress accumulation and rumination that disrupts evening wind-down, while DSIP at night restores restorative sleep that is essential for next-day stress resilience. Adequate deep sleep is required for emotional memory processing and HPA axis recovery — without it, anxiety compounds daily. This stack breaks that cycle through gentle, non-addictive peptide mechanisms that support rather than override natural neurotransmitter function. The beginner classification reflects the clean side-effect profiles of both compounds and their non-addictive nature.

Dosing Protocol

Selank

Twice per day· nasal

300 mcg

per dose

DSIP

nightly· subcutaneous

100 mcg

per dose

Goals & Evidence

Anxiety reductionStressCalmSleep onsetMood
Evidence tier:Human RCT

Warnings

  • Selank approved in Russia for anxiety. DSIP (Delta Sleep-Inducing Peptide) has limited but promising human data. Neither FDA-approved in US.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.